Cancer Family
Thoracic Neoplasm
CI-CAN-00000054Explore in graph →
Non-malignant2,893 active trials51 approved drugs626 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000054Explore in graph →
Clinical trials
12,163 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06726265 | Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004) | active not recruiting | Phase 3 | 756 | Immutep S.A.S.INDUSTRY | 27 | Mar 18, 2026 | clinicaltrials |
| NCT04802174 | Lurbinectedin With Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High-Grade Neuroendocrine Cancers | active not recruiting | Phase 1 / Phase 2 | 37 | National Cancer Institute (NCI)NIH |
| 1 |
| Mar 17, 2026 |
| clinicaltrials |
| NCT05456867 | A Multi-center, Non-interventional, Prospective Study of Durvalumab in Unresectable Locally Advanced NSCLC in Routine Clinical Practice in Russia(NIS durvalumab) | active not recruiting | — | 250 | AstraZenecaINDUSTRY | 1 | Mar 17, 2026 | clinicaltrials |
| NCT07396467 | Clinical Outcomes and Immunotherapy in Lung Cancer With Pulmonary Fibrosis(IPF-LC-IO) | active not recruiting | — | 200 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT05364073 | Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations | active not recruiting | Phase 1 | 160 | ArriVent BioPharma, Inc.INDUSTRY | 11 | Mar 13, 2026 | clinicaltrials |
| NCT04897022 | A Study of Pembrolizumab and Radiation Therapy in People With Mesothelioma | active not recruiting | Phase 1 | 7 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 12, 2026 | clinicaltrials |
| NCT05401786 | Anti-PD-1 Re-challenge After Immune Priming by Ipilimumab and Immune Boosting by Radiotherapy in Advanced NSCLC(RAD-IO) | active not recruiting | Phase 2 | 54 | The Netherlands Cancer InstituteOTHER | 1 | Mar 12, 2026 | clinicaltrials |
| NCT05853887 | Liquid Biopsy Based NGS in Newly Diagnosed NSCLC(iNUDGE) | active not recruiting | N/A | 260 | Charu AggarwalOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT06277388 | Evaluation of Impedance Cardiography for Assessing Hemodynamic Shifts in Patients With LA-NSCLC During Treatment. | active not recruiting | — | 231 | Sun Yat-sen UniversityOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT06301295 | Feasibility of Targeted Bronchial Washing for Molecular Testing by Next Generation Sequencing in Early-stage Lung Cancer | active not recruiting | N/A | 50 | Pusan National University HospitalOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT03875820 | Phase I Trial of Defactinib and VS-6766.(FRAME) | active not recruiting | Phase 1 | 87 | Institute of Cancer Research, United KingdomOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT05044468 | EXPAREL or Lidocane as Local Anesthetic in Patients Undergoing Pleuroscopy With Pleural Biopsy and Indwelling Pleural Catheter Placement | active not recruiting | Phase 2 | 80 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT05237453 | Pulmonary Magnetic Resonance-guided Online Adaptive Radiotherapy of Locally Advanced Non-Small Cell Lung Cancer(PUMA) | active not recruiting | N/A | 30 | University Hospital HeidelbergOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT05499390 | AK112 in Advanced Non-Small Cell Lung Cancer | active not recruiting | Phase 3 | 398 | AkesoINDUSTRY | 1 | Mar 9, 2026 | clinicaltrials |
| NCT05904379 | AK112 and AK104 With or Without Chemotherapy in Advanced Non-small Cell Lung Cancer | active not recruiting | Phase 1 / Phase 2 | 233 | AkesoINDUSTRY | 1 | Mar 9, 2026 | clinicaltrials |
| NCT02701699 | 18F-Fluoroazomycin Arabinoside (18F-FAZA) in Lung Cancer(FAZA Lung) | active not recruiting | N/A | 36 | University Health Network, TorontoOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT05254795 | Precision Medicine Randomized Clinical Trial Comparing Molecular Tumor Board Assisted Care to Usual Care(PRiMAL) | active not recruiting | N/A | 659 | Timothy MullettOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT03260491 | U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer | active not recruiting | Phase 1 | 312 | Daiichi SankyoINDUSTRY | 6 | Mar 5, 2026 | clinicaltrials |
| NCT05166616 | Minnelide and Osimertinib for the Treatment of Advanced EGFR Mutated Non-Small Cell Lung Cancer | active not recruiting | Phase 1 | 8 | City of Hope Medical CenterOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT06883630 | A Phase Ib Study of RC148 as Monotherapy or Combination for Locally Advanced or Metastatic NSCLC | active not recruiting | Phase 1 | 121 | RemeGen Co., Ltd.INDUSTRY | 1 | Mar 5, 2026 | clinicaltrials |
| NCT03223155 | Concurrent or Sequential Immunotherapy and Radiation Therapy in Patients With Metastatic Lung Cancer(COSINR) | active not recruiting | Phase 1 | 78 | University of ChicagoOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT03705806 | Palliative Thoracic ImmunoRT | active not recruiting | — | 12 | University Health Network, TorontoOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT04347161 | Implementation Strategies for Monitoring Adherence in Real Time(iSMART) | active not recruiting | N/A | 75 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT04819100 | A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)(LIBRETTO-432) | active not recruiting | Phase 3 | 152 | Eli Lilly and CompanyINDUSTRY | 32 | Mar 4, 2026 | clinicaltrials |
| NCT05184712 | Phase 3 Clinical Study of AK112 for NSCLC Patients | active not recruiting | Phase 3 | 322 | AkesoINDUSTRY | 1 | Mar 4, 2026 | clinicaltrials |
| NCT07449858 | 18F-FDG PET/CT Radiomics Models for Precision Diagnosis and Prognosis in NSCLC(PET-Rad-NSCLC) | active not recruiting | — | 500 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT05546268 | Study of Oral MRT-2359 in Selected Cancer Patients | active not recruiting | Phase 1 / Phase 2 | 174 | Monte Rosa Therapeutics, IncINDUSTRY | 1 | Mar 3, 2026 | clinicaltrials |
| NCT03164486 | First-in-Human Positron Emission Tomography Study Using the 18F-αvβ6-Binding-Peptide | active not recruiting | Early Phase 1 | 27 | Julie L. Sutcliffe, Ph.DOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT03598309 | Phase II Trial to Modulate Intermediate Endpoint Biomarkers in Former and Current Smokers | active not recruiting | Phase 2 | 19 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT04602533 | Efficacy and Safety of Standard of Care Plus Durvalumab in Patients With Limited Disease Small Cell Lung Cancer (DOLPHIN) | active not recruiting | Phase 2 | 105 | Michael HoppOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT01345851 | Image-Guided Hypofractionated Radiation Therapy With Stereotactic Body Radiation Therapy Boost and Combination Chemotherapy in Treating Patients With Stage II-III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery | active not recruiting | N/A | 29 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Feb 25, 2026 | clinicaltrials |
| NCT02716116 | A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer | active not recruiting | Phase 1 / Phase 2 | 334 | TakedaINDUSTRY | 10 | Feb 25, 2026 | clinicaltrials |
| NCT03774732 | PD-1 Inhibitor and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung Cancer(NIRVANA-LUNG) | active not recruiting | Phase 3 | 327 | UNICANCEROTHER | 2 | Feb 25, 2026 | clinicaltrials |
| NCT05280470 | Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC)(IDeate-Lung01) | active not recruiting | Phase 2 | 187 | Daiichi SankyoINDUSTRY | 8 | Feb 25, 2026 | clinicaltrials |
| NCT04428905 | Self-Management Survivorship Care in Stage I-III Non-small Cell Lung Cancer or Colorectal Cancer | active not recruiting | Phase 3 | 403 | City of Hope Medical CenterOTHER | 1 | Feb 24, 2026 | clinicaltrials |
| NCT04471727 | A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001) | active not recruiting | Phase 1 / Phase 2 | 232 | Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 1 | Feb 24, 2026 | clinicaltrials |
| NCT05587972 | Real World Treatment Experience of Patients With Breast, Lung, or GI Cancer or Multiple Myeloma Using Remote Symptom Monitoring | active not recruiting | N/A | 100 | Carevive Systems, Inc.INDUSTRY | 1 | Feb 23, 2026 | clinicaltrials |
| NCT03523546 | Oncology Episode Payment Model in Hawaii | active not recruiting | N/A | 7 | University of PennsylvaniaOTHER | 1 | Feb 20, 2026 | clinicaltrials |
| NCT03686007 | Multimedia Self-Management Intervention for Lung Cancer Surgery Family Caregivers and Patients | active not recruiting | N/A | 380 | City of Hope Medical CenterOTHER | 1 | Feb 20, 2026 | clinicaltrials |
| NCT04258813 | Onco-primary Care Networking to Support TEAM-based Care(ONE TEAM) | active not recruiting | N/A | 313 | Duke UniversityOTHER | 1 | Feb 20, 2026 | clinicaltrials |
| NCT02422381 | MK-3475 and Gemcitabine in Non-Small Cell Lung Cancer (NSCLC) | active not recruiting | Phase 1 / Phase 2 | 16 | Providence Health & ServicesOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT05721950 | A Study to Learn About Brigatinib Treatment Information Available in Chinese Participants With Non-Small-cell Lung Cancer (NSCLC)(Brilliant) | active not recruiting | — | 154 | TakedaINDUSTRY | 1 | Feb 18, 2026 | clinicaltrials |
| NCT03767348 | Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)(IGNYTE) | active not recruiting | Phase 2 | 340 | Replimune, Inc.INDUSTRY | 5 | Feb 13, 2026 | clinicaltrials |
| NCT06445192 | Evaluating the Impact of a Virtually Supervised Exercise Intervention and Group Counseling on Inflammation and the Microbiome of Smokers at High Risk for Lung Cancer, BE FIT Trial | active not recruiting | N/A | 65 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Feb 13, 2026 | clinicaltrials |
| NCT03830918 | Niraparib, Temozolomide and Atezolizumab in Treating Patients With Advanced Solid Tumors and Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line Chemotherapy | active not recruiting | Phase 1 / Phase 2 | 59 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT05714891 | Neoadjuvant Platform Trial in Non-Small Cell Lung Cancer | active not recruiting | Phase 2 | 4 | Canadian Cancer Trials GroupNETWORK | 1 | Feb 12, 2026 | clinicaltrials |
| NCT05239143 | P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors | active not recruiting | Phase 1 | 180 | Poseida Therapeutics, Inc.INDUSTRY | 1 | Feb 9, 2026 | clinicaltrials |
| NCT07312682 | Application of 4DCT-Based Pulmonary Ventilation Imaging in Lung Cancer Radiotherapy(FLAR-4DCT) | active not recruiting | — | 202 | The Second Affiliated Hospital of Chongqing Medical UniversityOTHER | 1 | Feb 9, 2026 | clinicaltrials |
| NCT02152631 | A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer(JUNIPER) | active not recruiting | Phase 3 | 453 | Eli Lilly and CompanyINDUSTRY | 21 | Feb 6, 2026 | clinicaltrials |
| NCT02514512 | Lung Cancer Radiotherapy Using Realtime Dynamic Multileaf Collimator (MLC) Adaptation And Radiofrequency Tracking(LIGHTSABR) | active not recruiting | N/A | 20 | Royal North Shore HospitalOTHER | 1 | Feb 6, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Mar 18, 2026source: clinicaltrials